PA
IBRX icon

PharVision Advisers’s ImmunityBio IBRX Stock Holding History

PharVision Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98K Buy
+11,198
New +$84.8K 1.85% 19

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PharVision Advisers's IBRX Position: Q2 2026 in Review

PharVision Advisers opened a new position in ImmunityBio (IBRX) in Q2 2026: 11,198 shares worth $98K. The stake represents 1.85% of the portfolio and ranks #19 among its holdings.

404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • PharVision Advisers held 11,198 shares of ImmunityBio worth $98K as of Q2 2026.
  • ImmunityBio was a new PharVision Advisers position in Q2 2026.
  • ImmunityBio made up 1.85% of PharVision Advisers's portfolio in Q2 2026, its #19 holding.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.